New Developments in Insomnia Medications of Relevance to Mental Health Disorders

被引:9
|
作者
Krystal, Andrew D. [1 ]
机构
[1] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27705 USA
关键词
Personalization; Insomnia; Comorbid psychiatric disorders; Suvorexant; Doxepin; Prazosin; Eszopiclone; POSTTRAUMATIC-STRESS-DISORDER; DOXEPIN; MG; GENERALIZED ANXIETY DISORDER; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; COMBAT VETERANS; SLEEP DISTURBANCE; TRAUMA NIGHTMARES; EFFICACY; SAFETY;
D O I
10.1016/j.psc.2015.08.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism matters." A new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders. This article reviews insomnia medications and discusses the implications for optimizing the treatment of insomnia occurring comorbid with psychiatric conditions.
引用
收藏
页码:843 / +
页数:19
相关论文
共 50 条
  • [1] New developments in perinatal mental health
    Austin, MP
    Priest, S
    ACTA PSYCHIATRICA SCANDINAVICA, 2004, 110 (05) : 321 - 322
  • [2] NEW DEVELOPMENTS IN MENTAL HEALTH AND COMMUNITY
    Fazenda, I
    PSILOGOS, 2009, 7 (1-2) : 111 - 119
  • [3] Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders
    Bradford, Ashley C.
    Lozano-Rojas, Felipe
    Shone, Hailemichael Bekele
    Bradford, W. David
    Abraham, Amanda J.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [4] The Diminished Pipeline for Medications to Treat Mental Health and Substance Use Disorders
    O'Brien, Peggy L.
    Thomas, Cindy Parks
    Hodgkin, Dominic
    Levit, Katharine R.
    Mark, Tami L.
    PSYCHIATRIC SERVICES, 2014, 65 (12) : 1433 - 1438
  • [5] Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders
    Castaldelli-Maia, Joao Mauricio
    de Oliveira, Victoria Camargos
    Irber, Flavia Mariana
    Blaas, Israel K.
    Angerville, Bernard
    Martins-da-Silva, Anderson Sousa
    Gimenes, Gislaine Koch
    Campos, Marcela Waisman
    Torales, Julio
    Ventriglio, Antonio
    Guillois, Carine
    El Ouazzani, Houria
    Gazaix, Lena
    Favre, Pascal
    Dervaux, Alain
    Apter, Gisele
    INTERNATIONAL REVIEW OF PSYCHIATRY, 2023, 35 (5-6) : 397 - 417
  • [6] MENTAL HEALTH DEVELOPMENTS IN NEW-BRUNSWICK
    SYKES, P
    CANADAS MENTAL HEALTH, 1970, 18 (06) : 16 - 21
  • [7] New developments in 2015 for Aging & Mental Health
    Zarit, Steven
    Orrell, Martin
    Chou, Kee-Lee
    AGING & MENTAL HEALTH, 2015, 19 (01) : 1 - 1
  • [8] Sleep, insomnia and neurological and mental disorders
    Riemann, Dieter
    JOURNAL OF SLEEP RESEARCH, 2019, 28 (04)
  • [9] Editorial: New players on the monoaminergic field: relevance to the mental disorders
    Dremencov, Eliyahu
    Jezova, Daniela
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Sleep, insomnia and mental health
    Palagini, Laura
    Hertenstein, Elisabeth
    Riemann, Dieter
    Nissen, Christoph
    JOURNAL OF SLEEP RESEARCH, 2022, 31 (04)